What the latest guidance shift means for American Healthcare REIT (AHR)

American Healthcare REIT (AHR) cut its 2026 net income guidance while highlighting a ninth straight quarter of double-digit same-store NOI growth and higher NFFO expectations, providing a mixed but detailed update on its outlook.

Recent guidance cuts on 2026 net income sit alongside raised same store NOI and NFFO outlook, and the stock’s 1 month share price return of 4.2% and 1 year total shareholder return of 57.66% suggest that momentum has been building rather than fading.

If you are looking beyond healthcare REITs for what could be moving next, this is a good time to scan 36 power grid technology and infrastructure stocks

With guidance for 2026 net income moving lower but NFFO and same store NOI guidance resetting higher, plus a reported 42% intrinsic discount, investors may question whether AHR remains undervalued or whether the market is already pricing in its future growth potential.

Most Popular Narrative: 14.4% Undervalued

With the most followed narrative putting American Healthcare REIT’s fair value at $57.92 versus a last close of $49.60, the gap comes down to how confident you are in its long term earnings and cash flow story.

The company's disciplined portfolio optimization, selling older, lower-quality assets and redeploying proceeds into modern, higher-acuity, and recently developed properties at below replacement cost, is described as a way to improve asset quality and accelerate future AFFO and earnings growth as new assets stabilize. Scalable operating initiatives, such as advanced revenue management systems and best in class benchmarking across operators, are cited as potential drivers of increased pricing power and operational efficiency, which in turn are expected to support net margin improvement and higher cash flows.

Want to see what sits behind that confidence in future cash flows and margins? The narrative leans on aggressive revenue expansion, rising profitability, and a rich earnings multiple built into the fair value. Curious which assumptions really carry that $57.92 figure and how they stack up over time?

Result: Fair Value of $57.92 (UNDERVALUED)

However, that story can crack if occupancy levels slow in Trilogy and SHOP, or if pressure on outpatient medical tenants drags on portfolio margins.

Another Angle on AHR’s Valuation

The fair value narrative paints AHR as 14.4% undervalued at $57.92, but the current P/E of 136.3x tells a different story. It sits well above the Global Health Care REITs average of 24.2x and the fair ratio of 48.5x, which points to meaningful valuation risk if sentiment cools.

Next Steps

Seeing mixed signals on valuation and risks? Take this opportunity to review the numbers yourself and decide where you stand with 3 key rewards and 3 important warning signs

Looking for more investment ideas?

If AHR has your attention, do not stop here. Widening your watchlist with fresh ideas now could be the edge you regret skipping later.

• Target potential value opportunities by scanning 51 high quality undervalued stocks, which already combine quality fundamentals with pricing that may not reflect their full potential.
• Strengthen the income side of your portfolio by reviewing 12 dividend fortresses, built around higher yielding stocks that still focus on resilience.
• Prioritize resilience and support a smoother investment experience by checking 72 resilient stocks with low risk scores, which filter for companies with lower overall risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.